A 9-year-old girl is brought to the emergency room by her parents with severe shortness of breath, cough, and wheezing after playing with her friends in the garden. She has a history of bronchial asthma. Her vital signs are as follows: respiratory rate 39/min, pulse 121/min, blood pressure 129/67 mm Hg, and temperature 37.2°C (99°F). On physical exam, she looks confused and has bilateral diffuse wheezes on chest auscultation. Which of the following is the most appropriate drug to rapidly reverse her respiratory distress?
Q182
Which of the following correctly pairs a neurotransmitter with its location of synthesis?
Q183
A 49-year-old man presents to his primary care provider complaining of weakness and fatigue. He reports that he has started moving slower than normal and has noticed difficulty buttoning up his pants or tying his tie. He is accompanied by his wife who reports that he has started to move more slowly over the past 2 years. He has also become increasingly irritable and has had trouble sleeping. His past medical history is notable for hypertension, diabetes mellitus, and obesity. He takes enalapril and metformin. His family history is notable for multiple strokes in his mother and father. His temperature is 99°F (37.2°C), blood pressure is 140/90 mmHg, pulse is 90/min, and respirations are 17/min. On exam, strength is 4+/5 bilaterally in his upper extremities and 4/5 in his lower extremities. Some muscle atrophy is noted in his legs and feet. Patellar reflexes are 3+ bilaterally. He has a tremor in his right hand that diminishes when he is instructed to hold a pen in his hand. He is oriented to person, place and time. He states that he feels depressed but denies suicidal ideation. His physician prescribes multiple medications including a drug that is also indicated in the treatment of prolactinomas. Which of the following is the mechanism of action of this medication?
Q184
A 21-year-old woman comes to the physician because of a 4-month history of fatigue. She admits to binge eating several times per month, after which she usually induces vomiting for compensation. She exercises daily in an effort to lose weight. She is 168 cm (5 ft 6 in) tall and weighs 60 kg (132 lb); BMI is 21.3 kg/m2. Physical examination shows calluses on the knuckles and bilateral parotid gland enlargement. Oropharyngeal examination shows eroded dental enamel and decalcified teeth. Which of the following is the most appropriate pharmacotherapy for this patient's condition?
Q185
A 40-year-old woman comes to the physician for a preoperative examination before undergoing a planned elective cholecystectomy. She has a history of myasthenia gravis, for which she takes oral pyridostigmine. She has had occasional episodes of muscle weakness, blurred vision, and slurred speech recently. Physical examination shows mild ptosis bilaterally. The pupils are normal in size and reactive bilaterally. Muscle strength is 3/5 at the hips and shoulders. Sensory examination shows no abnormalities. After the administration of 10 mg of edrophonium, her ptosis resolves, and her proximal muscle strength improves to 5/5. This patient is most likely to benefit from which of the following interventions?
Q186
A 12-year-old girl is brought to the pediatrician by her father who is concerned about the child’s ability to sit in a moving vehicle. She frequently develops nausea and dizziness when riding in a car for more than 10 minutes. The child has vomited twice over the past month while riding in the car. Her symptoms are significantly impairing her ability to make it to school on time without having to stop and get out of the car. The child does well in school and has several close friends. On examination, the child is well-appearing and appropriately interactive. Dix-Hallpike maneuver is negative. Her gait is normal. Strength and range of motion are full and symmetric bilaterally in the upper and lower extremities. The father would like to know if there is anything his daughter can take to be able to sit in a moving vehicle without feeling ill. A medication with which of the following mechanisms of action is indicated to manage this patient’s symptoms?
Q187
A 67-year-old farmer presents to the emergency department with a chief complaint of unusual behavior. His wife states that since this morning he has experienced dryness and flushing of his skin while working outside. As the day went on, the patient found it exceedingly difficult to urinate and had to create significant abdominal pressure for a weak stream of urine to be produced. Currently, the patient seems confused and responds incoherently. The patient has a past medical history of Parkinson's disease, alcohol abuse, irritable bowel syndrome, anxiety, diabetes mellitus, hypertension, constipation and a suicide attempt when he was 23 years old. He is currently taking lisinopril, hydrochlorothiazide, metformin, insulin, benztropine, levodopa/carbidopa, and vitamin C. The only other notable symptoms this patient has experienced are recent severe seasonal allergies. On physical exam you note dry, flushed skin, and a confused gentleman. His temperature is 99.5°F (37.5°C), pulse is 112/min, blood pressure is 130/90 mmHg, respirations are 18/min, and oxygen saturation is 96% on room air. Lab values are ordered. Which of the following is the most likely cause of this patient's presentation?
Q188
A 70-year-old woman is brought to her physician by her daughter who reports that the patient has been increasingly confused and forgetful over the past year. The daughter reports that the patient has difficulty finding words, remembering names, and maintaining a conversation. She has gotten lost twice while driving. Her past medical history is known for obesity, diabetes, and atrial fibrillation. She takes metformin, glyburide, and warfarin. She drinks socially and has a 30 pack-year smoking history. Her family history is notable for Parkinson’s disease in her father and stroke in her mother. A head CT demonstrates sulcal widening and narrowing of the gyri. The physician decides to start the patient on a medication known to inhibit a cell surface glutamate receptor. Which of the following is a downstream effect of this medication?
Q189
A healthy mother gives birth to a child at 40 weeks of gestation. On examination, the child has ambiguous genitalia. A karyotype analysis reveals the presence of a Y chromosome. Additional workup reveals the presence of testes and a normal level of serum luteinizing hormone (LH) and testosterone. Which of the following is the most likely cause of this patient’s condition?
Q190
A 55-year-old college professor with a long-standing history of neuropathic pain presents to a medical clinic with weight loss and early morning awakening for the past several months. She feels as if she has no energy to go about her work. She complains that she is not as focused at work or home as she used to be and finds both her life and work unfulfilling. She has had these symptoms for the past 2 months. She was started on antidepressants in the past, but the antidepressants did not provide any significant improvement. She eventually improved and has been in remission for almost 1 year now. She would really like a simple treatment option to address both her neuropathic pain and her depression, and she is started on a tricyclic antidepressant. What safety advice is most important for this patient’s treatment plan?
Cholinergic/Adrenergic drugs US Medical PG Practice Questions and MCQs
Question 181: A 9-year-old girl is brought to the emergency room by her parents with severe shortness of breath, cough, and wheezing after playing with her friends in the garden. She has a history of bronchial asthma. Her vital signs are as follows: respiratory rate 39/min, pulse 121/min, blood pressure 129/67 mm Hg, and temperature 37.2°C (99°F). On physical exam, she looks confused and has bilateral diffuse wheezes on chest auscultation. Which of the following is the most appropriate drug to rapidly reverse her respiratory distress?
A. Inhaled cromolyn
B. Inhaled beclomethasone
C. Oral montelukast
D. Inhaled albuterol (Correct Answer)
E. Intravenous propranolol
Explanation: ***Inhaled albuterol***
- **Albuterol** is a **short-acting beta-2 adrenergic agonist (SABA)**, which provides rapid **bronchodilation** by relaxing the smooth muscles of the airways.
- It is the **first-line treatment** for acute asthma exacerbations, effectively relieving **shortness of breath**, **cough**, and **wheezing**.
*Inhaled cromolyn*
- **Cromolyn** is a **mast cell stabilizer** used for **prophylactic** treatment of asthma, preventing the release of inflammatory mediators.
- It has **no role** in the acute reversal of severe respiratory distress due to its delayed onset of action.
*Inhaled beclomethasone*
- **Beclomethasone** is an **inhaled corticosteroid (ICS)** used as a **controller medication** for long-term asthma management to reduce airway inflammation.
- It is not indicated for acute symptom relief because its **anti-inflammatory effects** take several hours or days to manifest.
*Oral montelukast*
- **Montelukast** is a **leukotriene receptor antagonist** used for asthma prevention and treatment of **exercise-induced bronchoconstriction**.
- Its onset of action is **too slow** to provide immediate relief for an acute and severe asthma exacerbation.
*Intravenous propranolol*
- **Propranolol** is a **non-selective beta-blocker**, which can cause **bronchoconstriction** and worsen asthma symptoms.
- It is **contraindicated** in patients with asthma and would be dangerous to administer in this situation.
Question 182: Which of the following correctly pairs a neurotransmitter with its location of synthesis?
A. Serotonin -- Raphe nucleus (Correct Answer)
B. Acetylcholine -- Nucleus accumbens
C. GABA -- Ventral tegmentum
D. Norepinephrine -- Caudate nucleus
E. Dopamine -- Locus coeruleus
Explanation: ***Serotonin -- Raphe nucleus***
- The **raphe nuclei** are a group of serotonin-producing neurons located in the **brainstem**, crucial for mood, sleep, and appetite regulation.
- **Serotonin** (5-HT) is synthesized from the amino acid **tryptophan** within these neurons.
*Acetylcholine -- Nucleus accumbens*
- **Acetylcholine** is primarily synthesized in the **basal forebrain (e.g., nucleus basalis of Meynert)** and the pontomesencephalic tegmental complex, not the nucleus accumbens.
- The **nucleus accumbens** is a key structure in the reward pathway, receiving dopaminergic input from the ventral tegmental area.
*GABA -- Ventral tegmentum*
- **GABA** (gamma-aminobutyric acid) is the main inhibitory neurotransmitter in the brain, widely distributed and synthesized from **glutamate** by glutamic acid decarboxylase (GAD) in GABAergic neurons.
- The **ventral tegmental area (VTA)** is primarily associated with **dopamine** synthesis and its release to the nucleus accumbens and prefrontal cortex.
*Norepinephrine -- Caudate nucleus*
- **Norepinephrine** is primarily synthesized in the **locus coeruleus**, a nucleus located in the pons, playing a role in arousal and attention.
- The **caudate nucleus** is part of the basal ganglia, involved in motor control, learning, and memory, and is rich in **dopamine** receptors.
*Dopamine -- Locus ceruleus*
- **Dopamine** is mainly synthesized in the **substantia nigra** and the **ventral tegmental area (VTA)**, which project to various brain regions involved in motor control, reward, and motivation.
- The **locus coeruleus** is the primary site for the synthesis of **norepinephrine**, not dopamine.
Question 183: A 49-year-old man presents to his primary care provider complaining of weakness and fatigue. He reports that he has started moving slower than normal and has noticed difficulty buttoning up his pants or tying his tie. He is accompanied by his wife who reports that he has started to move more slowly over the past 2 years. He has also become increasingly irritable and has had trouble sleeping. His past medical history is notable for hypertension, diabetes mellitus, and obesity. He takes enalapril and metformin. His family history is notable for multiple strokes in his mother and father. His temperature is 99°F (37.2°C), blood pressure is 140/90 mmHg, pulse is 90/min, and respirations are 17/min. On exam, strength is 4+/5 bilaterally in his upper extremities and 4/5 in his lower extremities. Some muscle atrophy is noted in his legs and feet. Patellar reflexes are 3+ bilaterally. He has a tremor in his right hand that diminishes when he is instructed to hold a pen in his hand. He is oriented to person, place and time. He states that he feels depressed but denies suicidal ideation. His physician prescribes multiple medications including a drug that is also indicated in the treatment of prolactinomas. Which of the following is the mechanism of action of this medication?
A. Activate dopamine receptors (Correct Answer)
B. Inhibit dopamine receptors
C. Prevent dopamine degradation into 3-O-methyldopa
D. Prevent dopamine degradation into 3,4-dihydroxyphenylacetic acid
E. Increase dopamine release
Explanation: ***Activate dopamine receptors***
- The patient's symptoms (tremor, slowness of movement, difficulty with fine motor tasks, fatigue, irritability, sleep trouble) along with the physician prescribing a medication concurrently used for **prolactinomas** strongly suggest **Parkinson's disease**, which is characterized by **dopamine deficiency**.
- Medications for Parkinson's disease that also treat prolactinomas (e.g., **bromocriptine**, **cabergoline**) are **dopamine agonists** that directly activate dopamine receptors.
*Inhibit dopamine receptors*
- Inhibiting dopamine receptors would worsen the symptoms of **Parkinson's disease**, as the disease is caused by a **deficiency in dopamine**.
- Antipsychotic medications, which inhibit dopamine receptors, are typically contraindicated in Parkinson's patients due to their potential to exacerbate motor symptoms.
*Prevent dopamine degradation into 3-O-methyldopa*
- This mechanism describes the action of **catechol-O-methyltransferase (COMT) inhibitors**, which prevent the breakdown of levodopa (a dopamine precursor) into 3-O-methyldopa.
- While used in Parkinson's disease, COMT inhibitors do not directly activate dopamine receptors and are not typically indicated for **prolactinomas**.
*Prevent dopamine degradation into 3,4-dihydroxyphenylacetic acid*
- This mechanism describes the action of **monoamine oxidase-B (MAO-B) inhibitors** (e.g., selegiline, rasagiline), which prevent the breakdown of dopamine into 3,4-dihydroxyphenylacetic acid (DOPAC).
- While MAO-B inhibitors are used in Parkinson's disease, they are not indicated for the treatment of **prolactinomas**.
*Increase dopamine release*
- While some drugs can increase dopamine release (e.g., **amantadine**), this is not the primary mechanism of medications used for both **Parkinson's disease** and **prolactinomas**.
- The most direct action relevant to treating both conditions is the direct activation of **dopamine receptors** by agonists.
Question 184: A 21-year-old woman comes to the physician because of a 4-month history of fatigue. She admits to binge eating several times per month, after which she usually induces vomiting for compensation. She exercises daily in an effort to lose weight. She is 168 cm (5 ft 6 in) tall and weighs 60 kg (132 lb); BMI is 21.3 kg/m2. Physical examination shows calluses on the knuckles and bilateral parotid gland enlargement. Oropharyngeal examination shows eroded dental enamel and decalcified teeth. Which of the following is the most appropriate pharmacotherapy for this patient's condition?
A. Venlafaxine
B. Orlistat
C. Mirtazapine
D. Buspirone
E. Fluoxetine (Correct Answer)
Explanation: ***Fluoxetine***
- **Fluoxetine** is the **first-line antidepressant** approved for the treatment of **bulimia nervosa**, especially at higher doses (e.g., 60 mg/day).
- It helps reduce the frequency of **binge eating** and **purging behaviors** and can also address co-occurring mood symptoms.
*Venlafaxine*
- **Venlafaxine** is an SNRI (serotonin-norepinephrine reuptake inhibitor) primarily used for **major depression** and **generalized anxiety disorder**.
- While effective for depression, it is not specifically recommended as first-line pharmacotherapy for **bulimia nervosa**.
*Orlistat*
- **Orlistat** is a **lipase inhibitor** used for weight loss by reducing dietary fat absorption.
- It is not indicated for the treatment of **bulimia nervosa** and could potentially worsen the patient's anxiety about weight and body image.
*Mirtazapine*
- **Mirtazapine** is an antidepressant that works by blocking alpha-2 adrenergic receptors and serotonin receptors, often used for **depression** and difficulties with **insomnia** or **poor appetite**.
- It is not the primary pharmacotherapeutic choice for **bulimia nervosa**, and its weight-gain side effect might be counterproductive in this context.
*Buspirone*
- **Buspirone** is an **anxiolytic** agent used to treat **generalized anxiety disorder**.
- It does not have established efficacy for core **bulimic symptoms** (binge eating, purging) or depression, making it less appropriate as a primary treatment.
Question 185: A 40-year-old woman comes to the physician for a preoperative examination before undergoing a planned elective cholecystectomy. She has a history of myasthenia gravis, for which she takes oral pyridostigmine. She has had occasional episodes of muscle weakness, blurred vision, and slurred speech recently. Physical examination shows mild ptosis bilaterally. The pupils are normal in size and reactive bilaterally. Muscle strength is 3/5 at the hips and shoulders. Sensory examination shows no abnormalities. After the administration of 10 mg of edrophonium, her ptosis resolves, and her proximal muscle strength improves to 5/5. This patient is most likely to benefit from which of the following interventions?
A. Initiate treatment with intravenous atropine
B. Increase the dose of pyridostigmine (Correct Answer)
C. Add glycopyrrolate as needed
D. Administer timed doses of edrophonium
E. Discontinue treatment with pyridostigmine
Explanation: ***Increase the dose of pyridostigmine***
- The rapid improvement in symptoms (ptosis resolution, improved muscle strength) after **edrophonium** administration indicates a **myasthenic crisis** or under-dosing of pyridostigmine.
- Edrophonium is a short-acting **acetylcholinesterase inhibitor**, and its positive effect suggests that the patient needs more acetylcholine at the neuromuscular junction, which can be achieved by increasing the dose of the long-acting acetylcholinesterase inhibitor, pyridostigmine.
*Initiate treatment with intravenous atropine*
- **Atropine** is an **anticholinergic** agent used to treat cholinergic crisis, which presents paradoxically with increased weakness but also severe muscarinic side effects (e.g., salivation, bradycardia, diarrhea).
- The positive response to edrophonium rules out cholinergic crisis; administering atropine would worsen the myasthenic symptoms.
*Add glycopyrrolate as needed*
- **Glycopyrrolate** is another **anticholinergic** agent, similar to atropine, often used to reduce muscarinic side effects associated with acetylcholinesterase inhibitors.
- While it may help with side effects, it would not address the underlying muscle weakness due to insufficient acetylcholine in myasthenia gravis and could exacerbate it.
*Administer timed doses of edrophonium*
- **Edrophonium** is a **very short-acting** drug with a half-life of only a few minutes, making it unsuitable for long-term therapeutic management of myasthenia gravis.
- Its primary use is diagnostic (Tensilon test) or to differentiate between myasthenic and cholinergic crises, not for chronic treatment.
*Discontinue treatment with pyridostigmine*
- **Pyridostigmine** is the mainstay treatment for myasthenia gravis, improving muscle strength by increasing acetylcholine at the neuromuscular junction.
- Discontinuing it would inevitably lead to a severe worsening of myasthenic symptoms, as the patient is clearly under-treated, not over-treated.
Question 186: A 12-year-old girl is brought to the pediatrician by her father who is concerned about the child’s ability to sit in a moving vehicle. She frequently develops nausea and dizziness when riding in a car for more than 10 minutes. The child has vomited twice over the past month while riding in the car. Her symptoms are significantly impairing her ability to make it to school on time without having to stop and get out of the car. The child does well in school and has several close friends. On examination, the child is well-appearing and appropriately interactive. Dix-Hallpike maneuver is negative. Her gait is normal. Strength and range of motion are full and symmetric bilaterally in the upper and lower extremities. The father would like to know if there is anything his daughter can take to be able to sit in a moving vehicle without feeling ill. A medication with which of the following mechanisms of action is indicated to manage this patient’s symptoms?
A. Muscarinic acetylcholine receptor antagonist (Correct Answer)
B. Beta-1 adrenergic receptor agonist
C. Nicotinic acetylcholine receptor agonist
D. Alpha-2 adrenergic receptor agonist
E. Dopamine receptor antagonist
Explanation: ***Muscarinic acetylcholine receptor antagonist***
- The patient's symptoms are consistent with **motion sickness**, which is primarily mediated by the **vestibular system** and involves **acetylcholine** and **histamine** pathways.
- **Anticholinergic drugs**, such as **scopolamine**, block muscarinic acetylcholine receptors, effectively reducing nausea and vomiting associated with motion sickness.
- Scopolamine is considered one of the most effective medications for motion sickness prophylaxis.
*Beta-1 adrenergic receptor agonist*
- **Beta-1 adrenergic receptor agonists** (e.g., dobutamine) increase heart rate and myocardial contractility and are used for conditions like **heart failure** or **cardiogenic shock**.
- They do not have a role in treating motion sickness or its associated nausea and dizziness.
*Nicotinic acetylcholine receptor agonist*
- **Nicotinic acetylcholine receptor agonists** (e.g., nicotine) act on autonomic ganglia and the neuromuscular junction.
- These agents are not indicated for motion sickness and could potentially worsen symptoms or cause other adverse effects.
*Alpha-2 adrenergic receptor agonist*
- **Alpha-2 adrenergic receptor agonists** (e.g., clonidine) are used to treat **hypertension** and **ADHD** due to their central sympatholytic effects.
- They are not effective for motion sickness and would not alleviate the described symptoms.
*Dopamine receptor antagonist*
- While some **dopamine receptor antagonists** (e.g., promethazine, metoclopramide) have antiemetic properties, their efficacy in motion sickness is primarily due to **antihistamine activity** (H1 receptor blockade) rather than dopamine antagonism.
- **Anticholinergics** (muscarinic antagonists) are more direct and effective for motion sickness as they specifically target the vestibular-acetylcholine pathway that mediates motion-induced nausea.
- Pure dopamine antagonists without antihistamine effects would not be the primary choice for this condition.
Question 187: A 67-year-old farmer presents to the emergency department with a chief complaint of unusual behavior. His wife states that since this morning he has experienced dryness and flushing of his skin while working outside. As the day went on, the patient found it exceedingly difficult to urinate and had to create significant abdominal pressure for a weak stream of urine to be produced. Currently, the patient seems confused and responds incoherently. The patient has a past medical history of Parkinson's disease, alcohol abuse, irritable bowel syndrome, anxiety, diabetes mellitus, hypertension, constipation and a suicide attempt when he was 23 years old. He is currently taking lisinopril, hydrochlorothiazide, metformin, insulin, benztropine, levodopa/carbidopa, and vitamin C. The only other notable symptoms this patient has experienced are recent severe seasonal allergies. On physical exam you note dry, flushed skin, and a confused gentleman. His temperature is 99.5°F (37.5°C), pulse is 112/min, blood pressure is 130/90 mmHg, respirations are 18/min, and oxygen saturation is 96% on room air. Lab values are ordered. Which of the following is the most likely cause of this patient's presentation?
A. Medication (Correct Answer)
B. Heat stroke
C. Alcohol
D. Infection
E. Insecticide exposure
Explanation: ***Medication***
- The patient's symptoms (dry skin, flushed skin, confusion, urinary retention, tachycardia) are consistent with **anticholinergic toxicity**, which can result from an overdose or accumulation of anticholinergic medications.
- The patient is taking **benztropine**, an anticholinergic used for Parkinson's disease, and experiencing severe seasonal allergies, suggesting he might have started taking an **over-the-counter antihistamine** (many of which have anticholinergic effects) which in combination with benztropine, could lead to toxicity.
*Heat stroke*
- While **flushed, dry skin** and **confusion** can occur in heat stroke, the patient's temperature (99.5°F) is not elevated enough to suggest heat stroke.
- The patient's significant **urinary retention** is not a primary or typical symptom of heat stroke.
*Alcohol*
- The patient has a history of alcohol abuse, but the described symptoms are not typical of acute alcohol intoxication or withdrawal, especially the prominent **dry skin**, **flushing**, and **urinary retention**.
- There is no mention of recent alcohol consumption or specific withdrawal symptoms like tremors or seizures.
*Infection*
- While **confusion** can be a symptom of infection, especially in the elderly, the constellation of other symptoms (**dry skin, flushed skin, urinary retention, tachycardia**) does not specifically point to a common infection.
- The patient's temperature is only mildly elevated, not strongly indicative of a severe infection.
*Insecticide exposure*
- Exposure to **organophosphate insecticides** would typically cause **cholinergic crisis**, characterized by symptoms like increased salivation, lacrimation, urination, defecation, gastrointestinal upset, and emesis (SLUDGE syndrome), which are the opposite of the patient's anticholinergic symptoms.
- There is no information suggesting exposure to insecticides, and the clinical picture does not align with cholinergic toxicity.
Question 188: A 70-year-old woman is brought to her physician by her daughter who reports that the patient has been increasingly confused and forgetful over the past year. The daughter reports that the patient has difficulty finding words, remembering names, and maintaining a conversation. She has gotten lost twice while driving. Her past medical history is known for obesity, diabetes, and atrial fibrillation. She takes metformin, glyburide, and warfarin. She drinks socially and has a 30 pack-year smoking history. Her family history is notable for Parkinson’s disease in her father and stroke in her mother. A head CT demonstrates sulcal widening and narrowing of the gyri. The physician decides to start the patient on a medication known to inhibit a cell surface glutamate receptor. Which of the following is a downstream effect of this medication?
A. Increased intracellular sodium
B. Decreased intracellular acetylcholine
C. Increased intracellular acetylcholine
D. Increased intracellular calcium
E. Decreased intracellular calcium (Correct Answer)
Explanation: ***Decreased intracellular calcium***
- The patient's symptoms (confusion, forgetfulness, difficulty finding words, getting lost while driving) and imaging findings (sulcal widening, gyral narrowing) are consistent with **Alzheimer's disease**.
- The medication described, which inhibits a **cell surface glutamate receptor**, is likely **memantine**. Memantine is an **NMDA receptor antagonist**, which works by blocking the excessive influx of **calcium** into neurons and thus preventing **excitotoxicity**.
*Increased intracellular sodium*
- While **NMDA receptor activation** does lead to an influx of **sodium** (and calcium), memantine's primary mechanism of action targets the prevention of excessive **calcium influx** to mitigate excitotoxicity. Blocking the NMDA receptor might lead to a slight decrease in sodium influx, but the most clinically relevant target of memantine for preventing neuronal damage is calcium.
- Ion channels like the **NMDA receptor** allow the passage of multiple ions, but specific therapeutic interventions often focus on the ion whose dysregulation is most detrimental in the disease state.
*Decreased intracellular acetylcholine*
- Alzheimer's disease is characterized by a **deficiency in acetylcholine**, and many medications (like cholinesterase inhibitors) aim to *increase* acetylcholine levels.
- Memantine's mechanism of action does not directly involve the modulation of **acetylcholine** levels; it primarily affects the glutamatergic system.
*Increased intracellular acetylcholine*
- While therapies for Alzheimer's disease often aim to **increase acetylcholine** (e.g., donepezil, rivastigmine), this is not the mechanism of action of the medication described (a glutamate receptor inhibitor).
- Memantine targets the **glutamatergic system**, specifically the NMDA receptor, rather than cholinergic pathways.
*Increased intracellular calcium*
- In Alzheimer's disease, **excessive intracellular calcium** influx through NMDA receptors is a key contributor to **excitotoxicity** and neuronal damage.
- The described medication (memantine) works by *blocking* these receptors, thereby *reducing* the influx of calcium, not increasing it.
Question 189: A healthy mother gives birth to a child at 40 weeks of gestation. On examination, the child has ambiguous genitalia. A karyotype analysis reveals the presence of a Y chromosome. Additional workup reveals the presence of testes and a normal level of serum luteinizing hormone (LH) and testosterone. Which of the following is the most likely cause of this patient’s condition?
A. Failed migration of neurons producing gonadotropin releasing hormone (GnRH)
B. Androgen receptor deficiency
C. 5-alpha reductase deficiency (Correct Answer)
D. Aromatase deficiency
E. Presence of two X chromosomes
Explanation: ***5-alpha reductase deficiency***
- This condition involves the inability to convert **testosterone** to the more potent **dihydrotestosterone (DHT)**, which is essential for external male genital development.
- The presence of **testes**, Y chromosome, and normal testosterone levels indicate proper testicular function but impaired peripheral androgen action on external genitalia, leading to **ambiguous genitalia**.
*Failed migration of neurons producing gonadotropin releasing hormone (GnRH)*
- This describes **Kallmann syndrome**, which typically presents with **hypogonadotropic hypogonadism** (low LH and testosterone), as well as anosmia.
- The patient's normal LH and testosterone levels rule out this condition.
*Androgen receptor deficiency*
- This would result in **androgen insensitivity syndrome (AIS)**, where cells cannot respond to androgen, despite normal or high levels of testosterone.
- Patients with complete AIS typically present with female external genitalia, blind vaginal pouch, absent uterus, and develop testes. However, the presence of ambiguous genitalia points more towards a partial effect, which can also be seen in AIS, but 5-alpha reductase deficiency more specifically captures the scenario of impaired external masculinization with normal internal male structures.
*Aromatase deficiency*
- This would typically lead to impaired conversion of androgens to estrogens, resulting in **virilization** in affected individuals (e.g., males presenting with tall stature and osteoporosis, females with virilization and primary amenorrhea).
- It would not cause ambiguous genitalia with normal testosterone and LH levels.
*Presence of two X chromosomes*
- A karyotype showing a Y chromosome has already ruled out the presence of two X chromosomes, which is characteristic of biological females.
- If a Y chromosome is present along with two X chromosomes (e.g., **Klinefelter syndrome**, XXY), it typically results in male appearance with **hypogonadism** and **gynecomastia**, but not ambiguous genitalia from birth if all sex-determining genes are functional.
Question 190: A 55-year-old college professor with a long-standing history of neuropathic pain presents to a medical clinic with weight loss and early morning awakening for the past several months. She feels as if she has no energy to go about her work. She complains that she is not as focused at work or home as she used to be and finds both her life and work unfulfilling. She has had these symptoms for the past 2 months. She was started on antidepressants in the past, but the antidepressants did not provide any significant improvement. She eventually improved and has been in remission for almost 1 year now. She would really like a simple treatment option to address both her neuropathic pain and her depression, and she is started on a tricyclic antidepressant. What safety advice is most important for this patient’s treatment plan?
A. The medication has a very short half-life.
B. The medication can cause agranulocytosis.
C. The medication can lower the seizure threshold.
D. This medication can be lethal at high doses. (Correct Answer)
E. The medication can cause serotonin syndrome.
Explanation: ***This medication can be lethal at high doses.***
- **Tricyclic antidepressants (TCAs)** have a narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is small, making them particularly dangerous in overdose.
- Due to their effects on cardiac ion channels, **overdoses can cause fatal arrhythmias** such as ventricular tachycardia and fibrillation, as well as seizures and coma.
*The medication has a very short half-life.*
- **TCAs typically have long half-lives**, often requiring once-daily dosing, which contradicts the statement that they have a very short half-life.
- A short half-life would mean the drug is quickly eliminated, not a primary safety concern for accidental or intentional overdose with TCAs.
*The medication can cause agranulocytosis.*
- **Agranulocytosis is a rare but severe side effect more commonly associated with antipsychotics** (e.g., clozapine) or certain antiepileptic drugs, not a typical or prominent side effect of TCAs.
- While all medications carry some risk of hematologic abnormalities, agranulocytosis is not a primary safety warning for TCAs.
*The medication can lower the seizure threshold.*
- While TCAs can indeed **lower the seizure threshold**, especially at higher doses or in susceptible individuals, the most critical safety concern leading to lethality in overdose is their cardiotoxicity.
- Seizures are a serious side effect, but **fatal cardiac arrhythmias** are the leading cause of death in TCA overdose.
*The medication can cause serotonin syndrome.*
- **Serotonin syndrome is a risk when TCAs are combined with other serotonergic agents** (e.g., SSRIs, MAOIs) due to additive effects on serotonin levels.
- However, in the context of a single TCA prescription, the most immediate and profound safety concern, especially regarding potential lethality at high doses, is not serotonin syndrome but rather cardiotoxicity.